Obesity Clinical Trial
Official title:
Transoral Gastric Volume Reduction as an Intervention for Weight Management
This study assesses weight loss from the Endoscopic Vertical Gastroplasty or Fogel
Gastroplasty (FG). The purpose of the study is to:
- Document that weight loss occurs (12 months)
- Determine if it alters general wellbeing (emotionally and physically)
This will be a prospective study evaluating the percentage of weight loss in patients that
have undergo the Endoscopic Vertical Gastroplasty or Fogel Gastroplasty (FG). Fogel's
Gastroplasty is a procedure where The subject will be placed under general anesthesia in
accordance with the Institution's standard practice. The procedure will last approximately
1-2 hours. Following induction of anesthesia, the overtube will be placed, a gastroscope will
be inserted to examine esophageal and gastric anatomy and re-confirm there are no anatomical
contraindications to the procedure. The gastroscope will also be used to record images of the
stomach prior to insertion of the OverStitch. Once the examination is complete the
gastroscope will be removed. The OverStitch system will then be inserted orally to the
per-operative site. CO2 will be used rather than air for the insufflation that is required
during the procedure to minimize abdominal distention. The physician will place an
interrupted suture pattern in a manner which partitions the greater curvature of the stomach
from the Angle of His to the level of the incisura, creating a tube-like passage for gastric
volume reduction. Afterwards, the remaining gastric volume will be reduced using a
circumferential running stitch. Once complete, the OverStitch system will be removed and a
standard gastroscope will be inserted to record post procedure endoscopic images.
Anthropometric measurements as Weight, Height, BMI and Waist Circumference will be collected
at Baseline, 3, 6 and 12 months after procedure
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |